Total Payments
$14,520
2024 Payments
$152.57
Companies
21
Transactions
200
Medicare Patients
6,002
Medicare Billing
$515,685
Payment Breakdown by Category
Consulting$10,900 (75.1%)
Food & Beverage$3,209 (22.1%)
Gifts$396.31 (2.7%)
Education$14.40 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $10,900 | 1 | 75.1% |
| Food and Beverage | $3,209 | 192 | 22.1% |
| Gift | $396.31 | 5 | 2.7% |
| Education | $14.40 | 2 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $11,050 | 10 | $0 (2022) |
| AbbVie Inc. | $1,443 | 101 | $0 (2023) |
| Janssen Scientific Affairs, LLC | $406.96 | 5 | $0 (2022) |
| Braintree Laboratories, Inc. | $396.31 | 5 | $0 (2024) |
| Janssen Biotech, Inc. | $316.69 | 29 | $0 (2024) |
| PFIZER INC. | $294.93 | 19 | $0 (2023) |
| Intercept Pharmaceuticals, Inc. | $99.97 | 1 | $0 (2017) |
| GENZYME CORPORATION | $83.88 | 3 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $77.66 | 3 | $0 (2023) |
| UCB, Inc. | $56.00 | 3 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $152.57 | 4 | Braintree Laboratories, Inc. ($81.81) |
| 2023 | $494.98 | 28 | AbbVie Inc. ($236.18) |
| 2022 | $710.20 | 40 | ABBVIE INC. ($375.82) |
| 2021 | $640.72 | 42 | AbbVie Inc. ($355.90) |
| 2020 | $206.48 | 13 | AbbVie Inc. ($130.27) |
| 2019 | $487.48 | 14 | Janssen Scientific Affairs, LLC ($197.99) |
| 2018 | $11,083 | 13 | Takeda Pharmaceuticals U.S.A., Inc. ($10,915) |
| 2017 | $744.49 | 46 | Janssen Biotech, Inc. ($166.62) |
All Payment Transactions
200 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.55 | General |
| Category: Immunology | ||||||
| 11/04/2024 | Braintree Laboratories, Inc. | SUFLAVE (Drug) | Gift | Cash or cash equivalent | $81.81 | General |
| Category: GI COLON PREP | ||||||
| 09/05/2024 | Merck Sharp & Dohme LLC | DIFICID (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/18/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Immunology | ||||||
| 10/25/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $26.20 | General |
| Category: Immunology | ||||||
| 10/23/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/09/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: IMMUNOLOGY | ||||||
| 09/28/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $3.40 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/22/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $9.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/12/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $5.77 | General |
| Category: IMMUNOLOGY | ||||||
| 08/29/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/29/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $9.16 | General |
| Category: IMMUNOLOGY | ||||||
| 08/24/2023 | Braintree Laboratories, Inc. | SUFLAVE (Drug) | Gift | Cash or cash equivalent | $81.81 | General |
| Category: GI COLON PREP | ||||||
| 08/15/2023 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.37 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 08/09/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $6.05 | General |
| Category: IMMUNOLOGY | ||||||
| 08/08/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $10.83 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/04/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: IMMUNOLOGY | ||||||
| 07/20/2023 | AbbVie Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/20/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.61 | General |
| Category: IMMUNOLOGY | ||||||
| 07/19/2023 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.13 | General |
| Category: Immunology | ||||||
| 07/17/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 07/10/2023 | AbbVie Inc. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $6.95 | General |
| Category: IMMUNOLOGY | ||||||
| 06/12/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: IMMUNOLOGY | ||||||
| 05/31/2023 | AbbVie Inc. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $19.40 | General |
| Category: IMMUNOLOGY | ||||||
| 05/15/2023 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 1,393 | 1,674 | $717,375 | $130,018 |
| 2022 | 24 | 1,506 | 1,891 | $762,305 | $138,520 |
| 2021 | 29 | 1,591 | 1,943 | $775,261 | $134,806 |
| 2020 | 26 | 1,512 | 1,830 | $603,975 | $112,341 |
Total Patients
6,002
Total Services
7,338
Medicare Billing
$515,685
Procedure Codes
104
All Medicare Procedures & Services
104 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 151 | 153 | $157,850 | $19,788 | 12.5% |
| 91110 | Imaging of digestive tract done from the inside of the digestive tract | Office | 2023 | 25 | 25 | $60,000 | $12,551 | 20.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 146 | 147 | $136,325 | $11,865 | 8.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 72 | 74 | $70,300 | $11,234 | 16.0% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 242 | 425 | $50,575 | $8,923 | 17.6% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 115 | 176 | $17,600 | $8,102 | 46.0% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 37 | 37 | $48,100 | $6,739 | 14.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 39 | 39 | $37,050 | $6,336 | 17.1% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2023 | 100 | 107 | $13,910 | $6,043 | 43.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 62 | 65 | $10,630 | $5,656 | 53.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 37 | $10,878 | $4,715 | 43.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $10,175 | $3,262 | 32.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 20 | 20 | $6,600 | $3,011 | 45.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 31 | 31 | $6,975 | $2,954 | 42.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 23 | 23 | $21,850 | $2,756 | 12.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 46 | 46 | $9,200 | $2,721 | 29.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 21 | 22 | $5,055 | $2,696 | 53.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 29 | $4,379 | $2,468 | 56.3% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 27 | 27 | $23,625 | $2,239 | 9.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 39 | $4,134 | $2,221 | 53.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 28 | $2,981 | $1,607 | 53.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 28 | 32 | $2,400 | $1,160 | 48.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 11 | 11 | $1,133 | $531.41 | 46.9% |
| 91200 | Measurement of liver stiffness | Office | 2023 | 23 | 23 | $4,600 | $363.95 | 7.9% |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an ind |